Ali A Habib

Title(s)Health Sciences Professor, Neurology
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-6832
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Correction to: Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurol Ther. 2023 Oct; 12(5):1591-1592. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. PMID: 37368226; PMCID: PMC10444721.
      View in: PubMed   Mentions:
    2. Advancements in targeted therapies for generalized acetylcholine receptor antibody positive myasthenia gravis: Beginnings of a paradigm shift. Eur J Neurol. 2023 Dec; 30(12):3644-3645. Habib AA, Schneider-Gold C. PMID: 37578121.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023 Nov; 68(5):762-766. Katyal N, Halldorsdottir K, Govindarajan R, Shieh P, Muley S, Reyes P, Leung KK, Mullen J, Milani-Nejad S, Korb M, Goyal NA, Mozaffar T, Goyal N, Habib AA, Muppidi S. PMID: 37695277.
      View in: PubMed   Mentions:    Fields:    
    4. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Front Public Health. 2023; 11:1147489. Hughes T, Anderson AEL, Habib AA, Perez K, Bergin C, Suchotliff S, Zvosec C, McDaniel D, Sato M, Whangbo A, Phillips G. PMID: 37275500; PMCID: PMC10235801.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurol Ther. 2023 Oct; 12(5):1573-1590. Regnault A, Morel T, de la Loge C, Mazerolle F, Kaminski HJ, Habib AA. PMID: 37166675; PMCID: PMC10444722.
      View in: PubMed   Mentions: 2  
    6. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023 05; 22(5):383-394. Bril V, Druzdz A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ, MG0003 study team. PMID: 37059507.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    7. Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials. Neurology. 2023 09 05; 101(10):442-451. Guptill JT, Benatar M, Granit V, Habib AA, Howard JF, Barnett-Tapia C, Nowak RJ, Lee I, Ruzhansky K, Dimachkie MM, Cutter GR, Kaminski HJ, for MGNet Clinical Trial Outcome Measure Working Group. PMID: 37076302; PMCID: PMC10491448.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    8. Primary lateral sclerosis natural history study - planning, designing, and early enrollment. Amyotroph Lateral Scler Frontotemporal Degener. 2023 08; 24(5-6):394-404. Mitsumoto H, Jang G, Lee I, Simmons Z, Sherman AV, Heitzman D, Sorenson E, Cheung K, Andrews J, Harms M, Shneider NA, Santella R, Paganoni S, Ajroud-Driss S, Fernandes JAM, Burke KM, Gwathmey K, Habib AA, Maragakis NJ, Walk D, Fournier C, Heiman-Patterson T, Wymer J, Diaz F, Scelsa SN, Elman L, Genge A, Goutman SA, Hayat G, Jawdat O, Johnston WS, Joyce NC, Kasarskis EJ, Kisanuki YY, Lomen-Hoerth C, Pulley MT, Shah JS, Shoesmith C, Zinman L, PLS Natural History Study Group.. PMID: 36576200.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    9. Attitudes Toward Noninterventional Observational Studies in US and Australian Patients With Sporadic Inclusion Body Myositis. J Clin Neuromuscul Dis. 2020 Jun; 21(4):246-247. Mathew V, Wencel M, Habib AA, Goyal NA, Needham M, Mozaffar T. PMID: 32453104.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve. 2020 11; 62(5):579-592. Habib AA, Ahmadi Jazi G, Mozaffar T. PMID: 32462710.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):582-592. Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MG Study Group, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. PMID: 32065623; PMCID: PMC7042797.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    12. The neuropathology of leprosy. Arch Neurol. 2002 Jan; 59(1):138-40. Habib AA, Mozaffar T. PMID: 11790242.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Ali's Networks
    Concepts (38)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-2-gbbe5f151 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California